XML 55 R15.htm IDEA: XBRL DOCUMENT
v2.4.0.8

Related Party Transactions | 3 Months Ended | 15 Months Ended
--- | --- | ---
Dec. 31, 2013 | Dec. 31, 2013
Related Party Transactions [Text Block] |
Note 8 | Related Party Transactions
| The following amounts have been donated to the Company by the directors:
|  |  |  |  |  |  |  |  | January 23, 2004 |
|  |  | Three months ended December 31, |  |  | (Date of Inception) |
|  |  | 2013 |  |  | 2012 |  |  | to September 30, 2013 |
| Management fees | $ | - |  | $ | - |  | $ | 14,625 |
| Rent |  | - |  |  | - |  |  | 3,750 |
| Debt for given by directors |  | - |  |  | - |  |  | 33,666 |
|  | $ | - |  | $ | - |  | $ | 52,041 |
During the three months ended December 31, 2013, the Company was charged consulting fees totaling $Nil (2012: $70,418) by directors, officers and companies controlled by directors and officers of the Company. As of December 31, 2013, included in accounts payable and accrued liabilities was $28,851 (September 30, 2013: $30,447) owing to directors and officers of the Company and a former director and officer of the Company. During the year ended September 30, 2013, pursuant to an employment agreement with the President, Chief Executive Officer, Chief Financial Officer, Secretary and Treasurer, and Director, of the Company, the Company:
| i) | granted 2,000,000 fully vested share purchase options exercisable at $0.40 per share until July 5, 2023. No stock based compensation expense has been recognized during the three months ended December 31, 2013 and 2012 in connection with these options. The Company recognized stock based compensation expense of $1,002,500 during the year ended September 30, 2013 in connection with these options.
| ii) | issued 4,000,000 shares of restricted common stock that vest as follows:
25% upon the Company starting a Phase Ib/IIb human study 25% upon the Company in-licensing additional assets in clinical or pre-clinical stage 25% upon the Company securing additional non-dilutive equity funding in 2013 of at least $5,000,000 with a share price higher than the previous funding. 25% upon the Company obtaining a listing on a major stock exchange. No stock-based compensation has been recorded in connection with the issuance of these shares in the financial statements to December 31, 2013 as none of the performance conditions have yet been met. |
Note 8 | Related Party Transactions
| The following amounts have been donated to the Company by the directors:
|  |  |  |  |  |  |  |  | January 23, 2004 |
|  |  | Year ended September 30, |  |  | (Date of Inception) |
|  |  | 2013 |  |  | 2012 |  |  | to September 30, 2013 |
| Management fees | $ | - |  | $ | - |  | $ | 14,625 |
| Rent |  | - |  |  | - |  |  | 3,750 |
| Debt forgiven by directors |  | - |  |  | - |  |  | 33,666 |
|  | $ | - |  | $ | - |  | $ | 52,041 |
During the year ended September 30, 2013, the Company was charged consulting fees totaling $81,072 (2012: $479,434) by directors, officers and a significant shareholder of the Company. As at September 30, 2013, included in accounts payable and accrued liabilities is $30,447 (2012: $127,452) owing to directors and officers of the Company and a former director and officer of the Company. On July 5, 2013, pursuant to an employment agreement with the newly appointed President, Chief Executive Officer, Chief Financial Officer, Secretary and Treasurer, and Director, of the Company, the Company:
| i) | granted 2,000,000 fully vested share purchase options exercisable at $0.40 per share until July 5, 2023. The Company recognized stock based compensation expense of $1,002,500 (2012: $Nil) during the year ended September 30, 2013 in connection with these options.
| ii) | issued 4,000,000 shares of restricted common stock that vest as follows:
| • | 25% upon the Company starting a Phase Ib/IIb human study
| • | 25% upon the Company in-licensing additional assets in clinical or pre-clinical stage
| • | 25% upon the Company securing additional non-dilutive equity funding in 2013 of at least $5,000,000 with a share price higher than the previous funding.
| • | 25% upon the Company obtaining a listing on a major stock exchange.
No stock-based compensation has been recorded in connection with the issuance of these shares in the financial statements for the year ended September 30, 2013 as none of the performance conditions have yet been met.

X
- Definition The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph b -Article 3A Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(k)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph k -Article 4 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864 + Details
Name: | us-gaap_RelatedPartyTransactionsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration